Analyzing Quantrx Biomedical (OTCMKTS:QTXB) and Haemonetics (OTCMKTS:HAE)

Quantrx Biomedical (OTCMKTS:QTXB) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility and Risk

Quantrx Biomedical has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Quantrx Biomedical and Haemonetics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Quantrx Biomedical N/A N/A -$740,000.00 N/A N/A
Haemonetics $967.58 million 6.24 $55.02 million $2.39 49.84

Haemonetics has higher revenue and earnings than Quantrx Biomedical.

Insider & Institutional Ownership

99.3% of Haemonetics shares are held by institutional investors. 21.9% of Quantrx Biomedical shares are held by company insiders. Comparatively, 1.3% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Quantrx Biomedical and Haemonetics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quantrx Biomedical 0 0 0 0 N/A
Haemonetics 0 0 5 0 3.00

Haemonetics has a consensus price target of $144.80, indicating a potential upside of 21.56%. Given Haemonetics’ higher probable upside, analysts plainly believe Haemonetics is more favorable than Quantrx Biomedical.

Profitability

This table compares Quantrx Biomedical and Haemonetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quantrx Biomedical N/A N/A -104.40%
Haemonetics 6.90% 24.59% 12.34%

Summary

Haemonetics beats Quantrx Biomedical on 9 of the 11 factors compared between the two stocks.

Quantrx Biomedical Company Profile

QuantRx Biomedical Corporation engages in the development and commercialization patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infections, urinary incontinences, general catamenial uses, and other medical needs. It also provides InSync, a feminine hygienic interlabial padand; Unique miniform, which is available as a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad, for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. The company was incorporated in 1986 and is based in Tualatin, Oregon.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Receive News & Ratings for Quantrx Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantrx Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.